JP2021519580A5 - - Google Patents

Info

Publication number
JP2021519580A5
JP2021519580A5 JP2020552225A JP2020552225A JP2021519580A5 JP 2021519580 A5 JP2021519580 A5 JP 2021519580A5 JP 2020552225 A JP2020552225 A JP 2020552225A JP 2020552225 A JP2020552225 A JP 2020552225A JP 2021519580 A5 JP2021519580 A5 JP 2021519580A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain containing
signaling domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020552225A
Other languages
English (en)
Japanese (ja)
Other versions
JP7549533B2 (ja
JP2021519580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024441 external-priority patent/WO2019191339A1/en
Publication of JP2021519580A publication Critical patent/JP2021519580A/ja
Publication of JP2021519580A5 publication Critical patent/JP2021519580A5/ja
Application granted granted Critical
Publication of JP7549533B2 publication Critical patent/JP7549533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020552225A 2018-03-28 2019-03-27 キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用 Active JP7549533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649499P 2018-03-28 2018-03-28
US62/649,499 2018-03-28
PCT/US2019/024441 WO2019191339A1 (en) 2018-03-28 2019-03-27 Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof

Publications (3)

Publication Number Publication Date
JP2021519580A JP2021519580A (ja) 2021-08-12
JP2021519580A5 true JP2021519580A5 (cg-RX-API-DMAC7.html) 2022-04-04
JP7549533B2 JP7549533B2 (ja) 2024-09-11

Family

ID=66626002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552225A Active JP7549533B2 (ja) 2018-03-28 2019-03-27 キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用

Country Status (11)

Country Link
US (1) US20210024607A1 (cg-RX-API-DMAC7.html)
EP (1) EP3774869A1 (cg-RX-API-DMAC7.html)
JP (1) JP7549533B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210024441A (cg-RX-API-DMAC7.html)
CN (1) CN112218886B (cg-RX-API-DMAC7.html)
AU (1) AU2019243153A1 (cg-RX-API-DMAC7.html)
CA (1) CA3093969A1 (cg-RX-API-DMAC7.html)
IL (1) IL277587A (cg-RX-API-DMAC7.html)
MX (1) MX2020010235A (cg-RX-API-DMAC7.html)
RU (1) RU2020135106A (cg-RX-API-DMAC7.html)
WO (1) WO2019191339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064076A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
DK3688032T3 (da) 2017-09-26 2025-12-15 Cero Therapeutics Holdings Inc Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder
RU2020135107A (ru) 2018-03-28 2022-04-29 Серо Терапьютикс, Инк. Клеточные иммунотерапевтические композиции и их применения
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
US20240058446A1 (en) 2019-10-03 2024-02-22 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
CA3173673A1 (en) * 2020-04-23 2021-10-28 The Regents Of The University Of California Genetically engineered phagocytes, and related compositions, vectors, methods and systems
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
JP7868033B2 (ja) * 2020-08-14 2026-06-01 セロ・セラピューティクス・ホールディングス・インコーポレイテッド キメラtim受容体およびその使用
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
CN112194726B (zh) * 2020-09-02 2023-06-23 沣潮医药科技(上海)有限公司 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用
EP4240367A4 (en) * 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
CN116916940A (zh) * 2020-11-04 2023-10-20 美洛德生物医药公司 工程化嵌合融合蛋白组合物及其使用方法
KR20230118850A (ko) * 2020-11-18 2023-08-14 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 t 세포 및 방법
US20240148868A1 (en) * 2021-03-18 2024-05-09 University Of Florida Research Foundation, Incorporated Chimeric phagocytic receptors for treatment of neurodegenerative disorders
KR20240022465A (ko) * 2021-04-28 2024-02-20 산퀸 아이피 비.브이. 키메라 Fc-알파 수용체 및 그것의 용도
WO2022234976A1 (ko) * 2021-05-04 2022-11-10 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
WO2023286088A1 (en) * 2021-07-16 2023-01-19 Indian Institute Of Science Education And Research Bhopal Methods and compositions for viral vector transduction
FI4376874T3 (fi) 2021-07-28 2026-04-08 Cero Therapeutics Holdings Inc Kimeerisiä tim4-reseptoreita ja niiden käyttöjä
US20240408204A1 (en) * 2021-10-28 2024-12-12 The Regents Of The University Of California Methods of Treating Lymphoma with a Phagocyte Having a Chimeric Antigen Receptor
EP4486365A4 (en) * 2022-03-01 2026-02-11 Hemogenyx Pharmaceuticals Llc CHIMERA BAIT RECEIVERS AND THEIR USES
CA3245554A1 (en) * 2022-03-18 2023-09-21 The Regents Of The University Of Colorado, A Body Corporate Genetically modified T lymphocyte co-receptors and their methods of use
CN114806912A (zh) * 2022-04-06 2022-07-29 中国海洋大学 高效表达菌丝霉素的重组工程菌及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US8709412B2 (en) * 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2016019300A1 (en) * 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7032304B2 (ja) * 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球/マクロファージおよびその使用
WO2018031419A1 (en) * 2016-08-12 2018-02-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
WO2018064076A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
EP3876977A1 (en) * 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis

Similar Documents

Publication Publication Date Title
JP2021519301A5 (cg-RX-API-DMAC7.html)
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
RU2020135107A (ru) Клеточные иммунотерапевтические композиции и их применения
JP2022113880A5 (cg-RX-API-DMAC7.html)
JP2021514631A5 (cg-RX-API-DMAC7.html)
JP2018521628A5 (cg-RX-API-DMAC7.html)
JP7725031B2 (ja) Cd7を標的にするキメラ抗原受容体及びその使用
AU2016343809B2 (en) Compositions and methods for treatment of cancer
JP2020511136A5 (cg-RX-API-DMAC7.html)
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP2025028239A5 (cg-RX-API-DMAC7.html)
JP2020114264A5 (cg-RX-API-DMAC7.html)
JP2024534471A5 (cg-RX-API-DMAC7.html)
Peipp et al. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
HRP20201906T1 (hr) Označene kimerne efektorske molekule i njihovi receptori
JP2015527070A5 (cg-RX-API-DMAC7.html)
JP2020517295A5 (cg-RX-API-DMAC7.html)
JP2023527530A (ja) 同種異系移植のための操作された免疫細胞
JP2024534417A5 (cg-RX-API-DMAC7.html)
CA3054304A1 (en) Compositions and methods for treatment of cancer
JP2021532742A5 (cg-RX-API-DMAC7.html)
JP2017531687A5 (cg-RX-API-DMAC7.html)
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
US12077598B2 (en) Chimeric antigen receptors with mutated CD28 phosphorylation sites
JP2022513460A5 (cg-RX-API-DMAC7.html)